TD Cowen analyst Ritu Baral downgraded Avidity Biosciences (RNA) to Hold from Buy with a price target of $74, down from $78, after the company entered into a merger agreement with Novartis (NVS) for $72 per share.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Hold Rating Issued Amid Avidity Biosciences Acquisition and Strategic Restructuring
- Warner Bros. Discovery upgraded, F5 downgraded: Wall Street’s top analyst calls
- Avidity Biosciences downgraded to Neutral from Buy at Citi
- Avidity Biosciences downgraded to Neutral from Buy at Chardan
- Avidity Biosciences downgraded to Sector Perform from Outperform at RBC Capital